Abstract
Thromboxane A 2 (TXA 2 ) and prostacyclin (PGI 2 ) are two labile products formed from arachidonic acid by the way of cyclooxygenase. An overproduction of thromboxane A 2 has been detected in a series of diseases whereby this prostanoid is assumed to contribute to the underlying pathomechanisms by its potent stimulation of platelet aggregation and smooth muscle contraction. This increased TXA 2 biosynthesis is frequently accompanied by a stimulation of prostacyclin formation which is one of the most potent inhibitors of platelet aggregation and smooth muscle contraction. Therefore, TXA 2 prostaglandin endoperoxide H 2 receptor antagonists, thromboxane synthase inhibitors and drugs which combine both activities have been developed with the aim to suppress the formation and/or the action of thromboxane A 2 . Since prostacyclin has been demonstrated to counterbalance the pathological effects of TXA 2 , several PGI 2 agonists have also been developed. This review will highlight the evolution and some of the latest findings in the field of prostacyclin and thromboxane A 2 modulators mainly those which are under clinical evaluation or marketed.
Keywords: thromboxane A2 TXA2, prostacylin modulators, TXA2 biosynthesis, prostaglandin endoperoxide H2 receptor antagonists, thormboxane synthase inhibitors, TXSIs, TXA2 PGH2 receptor antagonists TXRAs, Prostanoid thromboxane A2 receptor antagonists, Non Prostanoid thromboxane A2 receptor antagonists, sulotroban, Combined thromboxane A2 receptor antagonists, prostaglandin D2, prostaglandin E2, prostaglandin H2, prostaglandin G2, prostaglandin F2
Current Medicinal Chemistry
Title: New Trends in Thromboxane and Prostacyclin Modulators
Volume: 7 Issue: 6
Author(s): Jean -Michel Dogne, Xavier de Leval, Jacques Delarge, Jean -Louis David and Bernard initial Masereel
Affiliation:
Keywords: thromboxane A2 TXA2, prostacylin modulators, TXA2 biosynthesis, prostaglandin endoperoxide H2 receptor antagonists, thormboxane synthase inhibitors, TXSIs, TXA2 PGH2 receptor antagonists TXRAs, Prostanoid thromboxane A2 receptor antagonists, Non Prostanoid thromboxane A2 receptor antagonists, sulotroban, Combined thromboxane A2 receptor antagonists, prostaglandin D2, prostaglandin E2, prostaglandin H2, prostaglandin G2, prostaglandin F2
Abstract: Thromboxane A 2 (TXA 2 ) and prostacyclin (PGI 2 ) are two labile products formed from arachidonic acid by the way of cyclooxygenase. An overproduction of thromboxane A 2 has been detected in a series of diseases whereby this prostanoid is assumed to contribute to the underlying pathomechanisms by its potent stimulation of platelet aggregation and smooth muscle contraction. This increased TXA 2 biosynthesis is frequently accompanied by a stimulation of prostacyclin formation which is one of the most potent inhibitors of platelet aggregation and smooth muscle contraction. Therefore, TXA 2 prostaglandin endoperoxide H 2 receptor antagonists, thromboxane synthase inhibitors and drugs which combine both activities have been developed with the aim to suppress the formation and/or the action of thromboxane A 2 . Since prostacyclin has been demonstrated to counterbalance the pathological effects of TXA 2 , several PGI 2 agonists have also been developed. This review will highlight the evolution and some of the latest findings in the field of prostacyclin and thromboxane A 2 modulators mainly those which are under clinical evaluation or marketed.
Export Options
About this article
Cite this article as:
Dogne -Michel Jean, Leval de Xavier, Delarge Jacques, David -Louis Jean and Masereel initial Bernard, New Trends in Thromboxane and Prostacyclin Modulators, Current Medicinal Chemistry 2000; 7 (6) . https://dx.doi.org/10.2174/0929867003374868
DOI https://dx.doi.org/10.2174/0929867003374868 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prevention of Respiratory Syncytial Virus: A Review
Current Respiratory Medicine Reviews Telomeres, Senescence and Longevity: The Role of Oxidative Stress and Antioxidants
Current Pharmacogenomics Simulating the Interactions of Toxins with K+ Channels
Current Pharmaceutical Design Effects of Insulin on the Vasculature
Current Vascular Pharmacology Prognostic Parameters for Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke in an Asian Population
Current Neurovascular Research Metabolic and Cardiovascular Complications of Highly Active Antiretroviral Therapy for HIV Infection
Current HIV Research Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials Molecular Mechanisms Underlying Psychological Stress and Cancer
Current Pharmaceutical Design Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Herb-drug Interactions Involving Drug Metabolizing Enzymes and Transporters
Current Drug Metabolism Synthetic Sustained Gene Delivery Systems
Current Topics in Medicinal Chemistry Probiotics as Biotherapeutic Agents: Present Knowledge and Future Prospects
Current Pharmaceutical Design Caring for Children with Medical Complexity: Definitions, Challenges and Solutions
Current Pediatric Reviews Pharmacological Innovations for Posttraumatic Stress Disorder and Medication- Enhanced Psychotherapy
Current Pharmaceutical Design Dronedarone – A New Alternative for Management of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery New Agents – Manifold Consequences: The Management of Lung and Colorectal Cancer is Changing
Current Cancer Therapy Reviews Subject Index To Volum 2
Current Diabetes Reviews Developing New Anti-Arrhythmics: Clues from the Molecular Basis of Cardiac Ryanodine Receptor (RyR2) Ca2+-Release Channel Dysfunction
Current Pharmaceutical Design Insulin Resistance is Associated with Subclinical Vascular Injury in Patients with a Kidney Disease
Current Cardiology Reviews Quinoxalinone as a Privileged Platform in Drug Development
Mini-Reviews in Medicinal Chemistry